Roland Rick Perry is the Managing Director of Institutional Analyst Inc. (IA), an independent investment research and investor relations firm, as well as editor of nine industry specific investment reviews. One of the best one mile runners to come out of the Chicago area, he attended Southern Illinois University, Loyola of Chicago and UCLA on track scholarships, achieving an Olympic Qualifying time in the early eighties, right in time for the Olympic boycott in 1980.Roland began his career on the floor of the Chicago Board Options Exchange (CBOE) as a runner in 1974. He worked for a number of well respected investment banking firms such as Merrill Lynch, Paine Webber, AG Becker Paribas and Drexel Burnham Lambert, prior to launching his own firm in 1995. He is the founder of the Chicago Stock & Bond Club, Morgan & Weed and Blank Check Capital Corp., which recently participated in Wall Street’s first “Ultra Mini™” blank check offering, as President of Life Sciences Opportunities Inc., which successfully merged with Beverly Hills based “Dr Tattoff” the leading Tattoo removal company in the U.S., with over 250,000 treatments on more than 25,000 patients. Founded in 2004 and headquartered in Beverly Hills, CA, Dr. Tattoff clinics are currently located throughout Southern California, Texas, Arizona and Georgia. Soon to go public (sooner or later) after completion of necessary required steps.Featured by the New York Times, the Los Angeles Times, Us Weekly, In Touch, People, CNN, ABC, LA Ink, Dr. 90210 and numerous other print, on-air and online media outlets, Dr. Tattoff is widely recognized as a leading provider of laser tattoo removal and laser hair removal.Website: Investor website: SEC filings: SEC filings BamSEC: https://www.bamsec.com/companies/1294157/dr-tattoff-incCrunchbase: Insiders:Mr Perry has been quoted and/or interviewed in the New York Times, the Los Angeles Times, CBS MarketWatch, South China Morning Post, the London Register, the UK Register and featured in Australia's ABC televised broadcast Lateline, and in a featured segment piece on National Enquirer TV.IA is a leading publisher of news, perspective and market intelligence reports on the equity markets. Working with publicly traded corporations, the firm works with small-cap companies which have products and/or services which can best be described as "best of breed." To align itself with shareholders, IA typically seeks to have 90% of its retainer, represented by an equity stake in their client companies.Founded in 1995 and based in Chicago, the heart of the trading industry, Institutional Analyst has offices in Beverly Hills, CA, Chicago IL, Delray Beach, FL and Port Jefferson, NY. Our sites include:Internet Stock Review.comPatent Stock Review.com (on hold)Alternative Energy Stock Review.comPrivate Equity Stock Review.comMarine Exploration Stock ReviewIA Special Situation Research.ning.comBiotech Stock Review.comRestaurant Stock Review.comNational Stock Review.comStem Cell Stock Review.comBeverage Stock Review.comBlanket disclaimer for all of our postings: Important Distinction #1. First and foremost the Watch List is just that. A watch list. It is not a buy list. Meaning that there will be no buys or sale recommendations issued by the various Reviews. If this was a buy list, you can rest assured that we would crank up our Public Relations arm into high gear, full speed ahead and damn the torpedoes to make everyone know just how brilliant we were when we issued the original Watch List in 1998 with the average stock gaining 157% the first year.. Interviews on CNBC, articles in Barron's and accolades in the Wall Street Journal--the only thing we love more than money is praise and fame--but it just isn't going to happen. What the Reviews are...is a "news aggregation service". With the advent of the Internet, everyone knows what that term means. What it means to us is the following: We will follow the progress of as many industry specific related publicly traded stocks as humanly possible (The large, the small and the minuscule) and advise you of when they have reported news. As a subscriber to any of our Reviews, this means you will be able to broadly follow an entire industry right from a single e-mail. We will report who released news and point (with hyper links) to where the news can be found. We try to use Yahoo! Finance and Seeking Alpha as extensively as possible so we don't send you all over cyberspace. We love Yahoo and Seeking Alpha, you will too. Any decisions as to buy or sell however, are strictly up to you. Which leads to important distinction #2. How do we get paid? The Reviews are owned by a Public Relations firm (Institutional Analyst Inc.) that specializes in getting (or creating) coverage for publicly traded companies. As such, is important to note that anytime we say anything about a company, it is because the company is a client of our parent company, or because we would like them to be a client of our parent company. In a nutshell, you can throw out any thoughts of us being even a little bit impartial. It just ain't gonna happen. We love everyone. Institutional Analyst Inc. is an independent research and investor-relations consulting firm that publishes investment-research reports such as The Reviews on independently selected companies. While it is its intent to identify and research companies that it believes might prove to be profitable investments, The Review is not liable for any investment decisions by its readers. Neither The Reviews nor any report published by Institutional Analyst Inc., represent a solicitation to buy or sell the securities discussed within the report. It is strongly recommended that any purchase or sale decisions be discussed with a financial adviser or broker prior to completing any such purchase or sale decision. The information contained herein is provided as an information service only and is based upon sources deemed reliable, but not guaranteed by The Reviews. Past performance of previously featured companies does not guarantee the future success of any currently featured or mentioned company. The information contained herein is subject to change without notice, and The Reviews assumes no responsibility to update the information in this or any report published. Use of this or any report published by The Review may be subject to the applicable rules of certain self-regulatory organizations and the securities mentioned herein, which are traded Over The Counter, and may not be cleared for sale in certain states. Institutional Analyst Inc and/or its employees, officers, affiliates or members of their families may have long or short positions in any of the securities discussed in this or other reports published herein (and/or options or warrants relating thereto) and may purchase and or sell these securities, options or warrants from time to time in the open market or otherwise. Institutional Analyst Inc may derive compensation through research services and subscriptions and/or investor-relations consulting from the companies featured or mentioned in its reports. Write or call Institutional Analyst Inc for disclosure details as required by Rule 17b as it relates to individual issues. Institutional Analyst Inc., In no event shall The Reviews report be liable for direct, indirect, incidental or consequential damages resulting from the use of this information. The Reviews shall be indemnified and held harmless from any actions, claims, proceedings or liabilities with respect to the information herein. Institutional Analyst Inc is not a securitiesbroker-dealer, investment advisor or a securities exchange and is not registered as such with the Securities and Exchange commission nor any state securities regulation authority. Readers of this e-mail newsletter should recognize that the Reviews are only providing a delivery service to electronically transmit information to potential investors. In this respect, the Reviews are no different than the provider of any other delivery service such as the United States Post Office or any other express delivery service. Accordingly, investors should be aware that the Reviews have not evaluated nor investigated any of the companies listed in this e-mail to determine their merit or the risk of investment in any such company. The Reviews do not endorse any company listed herein and the Reviews do not represent that the information contained in any offering documents states all material facts or does not omit a material fact necessary to make the statements therein not misleading. email@example.com For specific company disclaimer, please visit any of our websites about disclaimers where we have been compensated are on each blog right-up front in big print, on each research report written and in the general disclaimer section. We have nothing to hide, our disclaimers are everywhere. As the majority of our compensation is in restricted stock, the better our clients perform (which we have no control over), the better we are compensated and vice versa. This is in sharp contrast to firms which only accept cash as compensation, and who really couldn't care less how the stock performs, as long as their check keeps coming in. We believe this puts us on the same page as shareholders and our readers, because we are in fact shareholders.
Looking for equity in business or real estate opportunities that have tremendous potential. Aggressive risk appetite. Prefer to add value as service provider, but will invest capital in most instances.
20+ years of small public company investing and advising.
I strive to give readers actionable information to make smart investment decisions with exchange traded funds and mutual funds with consideration to the risks involved. I am the founder of Key Financial Media LLC, which produces content and thought leadership for financial advisors and investment strategists.
My work has been published in Institutional Investor, FA Mag, Think Advisor, Plan Sponsor, The Street and other leading financial news sites. Before starting my own firm, I covered stocks, ETFs, mutual funds, economics and personal finance at Investor’s Business Daily for more than eight years.
Douglas H. Leighton
Doug is co-founder and a principal partner of Dutchess Capital, a Boston-headquartered global hedge fund, which has managed an investment portfolio of over $2 billion in transactional value. Doug oversees the fund’s risk management and facilitates all of the fund’s trading on worldwide exchanges. Doug manages deal origination in North America, Europe and Australia and is a member of the firm’s Investment Committee. Douglas has founded several companies and has mentored several startup and growth management teams. He has over two decades of experience in equity trading, investment banking, asset management and the skill set to offer advice to startups and growth companies alike. While the funds are industry agnostic, Douglas has been largely focused on the legal marijuana market for over the past 2 years, initially as an observer while he conducted due diligence for several deals, and now as an active investor and board member for several companies. He also sits on the Company Selection Committee of ArcView, the cannabis angel network as well as a member of the NCIA. Through the Fund and personally, Doug has made numerous investments in ancillary businesses to the cannabis industry, in addition to touching the plant. He is often asked to speak at conferences regarding the business side of the marijuana business. Douglas has held seats on various boards of public and private companies, in addition to serving on the boards of several non-profits.
Spent my entire 28 year career on Wall Street with over a decade at Bear Stearns. No "Wall Street Titan" in real life but WST is an alias that I've used for years on Yahoo so I use it when I write on SA. I have gained a significant amount of knowledge regarding the stem cell sector over the years and have recently launched a premium service covering this exciting area.
I am a resident surgeon. I've thoroughly enjoyed my medical training and am currently learning how to apply my medical expertise to my interest in the stock market. I am always reading and learning and hope that my contributions to the Seeking Alpha community may be useful to some. In my free time, I enjoy running with my dogs (and boy can Rhodesian Ridgebacks run), and eating out with my wife.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
I am a private investor based out of Toronto, Canada and I have been investing since 2003. After 8 years in Corporate Finance with a Canadian Telecom company I have decided to dedicate myself full-time to the capital markets. I write on Seeking Alpha to demonstrate my financial analysis and writing skills across a variety of industries and to take advantage of any story-based trading opportunity that may arise. My passion and greatest depth of knowledge is on Canadian small cap stocks and I consider my blog posts to be some of my best work. I am interested in any freelance opportunities that may arise outside of Seeking Alpha on Canadian or American listed stocks.
01. Alert you to new short sale ideas.
We spend the day reading. We have pretty sophisticated search engines which alert us new new short ideas, as they appear. Keep in mind, short-sellers usually get "public" with their ideas AFTER they have established a short position and the stock may already be nearing its downside price target. We just don't know, you have to read what they write to gain (hopefully) perspective. There could be instances where someone goes public with their short, which causes a lot of selling, which would enable the short to cover - buying what your selling. And we have noticed instance when they are getting devastated and they have to cover - and then they get real noisy - again with the potential for them to buy, what your selling
It's some of the dangers of the game. So seller beware.
02. Alert you to new short squeeze ideas.
We spend the day reading. We have pretty sophisticated search engines which alert us to potential short squeezes, as they appear. Keep in mind, longs usually get "public" with their ideas AFTER they have established a long position and the stock may already be nearing its upside price target. We just don't know, you have to read what they write to gain (hopefully) perspective. There could be instances where someone goes public with their idea, which causes a lot of buying, which would enable the long to sell what you're buying.
03. Our favorite Analysts.
Our favorite Analysts are individuals (most often a "team" of analysts, forensic accountants, traders and lawyers) who we have been following for years and who just amaze us at the uncanny work they do.
We've made money following these analyst and lost money..
How you use the information we gather is strictly up to you. We do not offer investment advice. One of the most valuable uses of the news we re-distribute (including for our own short-folio) isn't making money, but rather avoiding losing money. We can't tell you how many times a deep-digging short research analyst saved our butt, by alerting us to something we totally missed in a stock we were long. Happens at least once a month.
Yes some of their work might seem self serving, but so what. This isn't about killing the messenger, its about getting the message. So read what they have to say and then make a decision for yourself.
Also don't kill us. If we send you a news report about a stock you own and then it triples in a short squeeze after you sell, don't blame us. While our "favorite analysts" have some unbelievable track records, they are human and make mistakes. While we may be vouching for them implicitly by calling them our favorites, we DO NOT vouch for their individual ideas, we are just passing them along for you to read. Whether you take action or not, is strictly up to you.
On occasion when we feel what we find is a compelling story, either a short or a short squeeze, after hearing both the long and short STORY - we may venture to go long or go short (usually options - since we can't fathom unlimited risk on the short side) and issue our own "special report."
These reports too, are not investment advice and we are not are we investment advisors. We're just telling you what's going on in our head - which can change in a moment without notice as can our open long or short position. We may buy, sell or cover due to personal circumstances, which may be contrary to the trade and contrary to where we think the stock is eventually headed.
Sharon di Stefano has spent 20 years as an analyst, beginning her career at Smith Barney, Harris Upham & Co. specializing in medical devices, pharmaceuticals, healthcare information technology, and biopharmacology. Ms. di Stefano had also served as Senior Venture Officer for the Edison Innovation Fund, implemented through the New Jersey Economic Development Authority that provided funding for early-stage life sciences companies. Industry experience includes laboratory research for Johns Hopkins Hospital and the Department of Defense.
Ms. di Stefano received a Masters of Science degree, in Business, from Johns Hopkins University in 1986, and a Bachelor of Arts from the University of Delaware in 1984 with a minor in biology.
Ray Dirks has been a respected analyst on Wall Street for decades. Ray has written two books,” The Great Wall Street Scandal” and “Heads You Win, Tails You Win”, published by McGraw-Hill and Bantam Books respectively.
Dirks opened his own securities analysis firm after gaining much attention in the financial press during the 1970s and 1980s.
Ray earned his place in the history books while working as a securities research analyst. He got a tip from a disgruntled employee of a company called Equity Funding that this firm had built its business model upon massive commercial and accounting fraud. Most research analysts on Wall Street took Equity Funding's numbers at face value, and recommended the stock.
Dirks, however, began his own investigation, found the tip credible, then warned both his firm's top institutional clients (who sold out their positions) and the SEC. He also tried, unsuccessfully, to interest The Wall Street Journal in the story. It turned out that the tip was right, and Equity Funding eventually collapsed in a manner that would prefigure some of the scandals that have been seen on the Street today.
I am an activist investor in US and Chinese stocks. I was previously an investment banker in New York Hong Kong and London for 9 years, focused on Equity Capital Markets. I look at both long ideas and short ideas and typically focus on a small number on names where I can spend the time to conduct very deep research. I spend my time living between Los Angeles and Beijing, China.
Active investor and trader since my teens. I retired early from my career in healthcare administration and have been a full time investor for 5 years.
I write about 3D Printing Stocks on my site @ 3DPrintingStocks.com, as well as small and microcap stocks (no pinks or junk!) at MicrocapResearch.com
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. www.TheLifeSciencesReport.com
I approach investing as a social theorist and a cultural historian. As a result, I am a contrarian. Studying the history of financialization, I have to agree with value investors like Seth Klarman, George Soros, and John Quiggin that markets are ultimately inefficient. However, I am not an orthodox value-investor. I believe in diversified strategy so as to insure maximum gains while maintaining a "margin of safety." Understanding that markets will operate inefficiently, I sometimes find "playing the greater fool's game" will yield nice short term gains. I have been investing for five years and have had proven results. I offer unique insight on fundamentals that most analysts do not consider.
Cornelius Vanderbilt has done more than any other man to shape our idea of investing. He was the ultimate contrarian. As an investor he looked for both value and risk. His approach to markets is complex and contradictory but can be learned from.
B.A., NYU Gallatin School
M.A. CUNY Gradatuate Center [in progress]
I started a twitter. https://twitter.com/matt_finston
Andrew Goodwin holds a Ph.D. in the cellular and molecular basis of human disease, with research experience in infectious diseases and cancer. After 11 years as an academic scientist I now work on the regulatory side of drug development. Aside from my day job, I operate the websites BiotechDueDiligence and HSP90 Central that provide in-depth, reliable information and education for biotech investors and other readers. I have also contributed to Chimera Research Group, a publisher of subscription-based biopharmaceutical insight. In 2012 I was honored to be named one of the "Top 50 Industry Voices in Biotech" by FierceBiotech and Appeering. Visit my BiotechDueDiligence website for additional bio details.
The Investor Protection Association (IPA) is devoted to performing research, investigation and publication of information which concerns financial fraud and dishonest stock market practices taking place in companies that trade on stock exchanges in the United States, with a focus on small cap equities and penny stocks.
The most important purpose of our service is to educate and help hard working, decent investors by informing them of fraud and manipulation in specific stocks. By performing scrupulous and professional research, uncovering crucial information and publishing it, we may help these investors make a more informed decision and avoid losing substantial amounts of money.
On the other hand, our service also caters to sophisticated short-biased traders by providing excellent, in terms of risk-to-reward ratio, trading setups which occur primarily as a result of inflated prices in stocks which are subject to promotional campaigns (so called Pump & Dump).
Accounting Professor teaching financial accounting; PhD, CPA, CMA, CGMA. He holds a BSBA from the University of Arizona, a Macc. from the University of Arizona, and his PhD from Virginia
Tech. He worked in public accounting, industry, as a CFO, a government auditor for the California Auditor General and in litigation support. His publications have been used and filed in Court proceedings by the Securities and Exchange Commission, he has been quoted in the Wall Street Journal, and his background includes litigation support and expert testimony in cases involving business litigation (e.g., Ford, GM, and so on) in CA, AZ, TX, NV and MN. He enjoys trading stocks and securities, teaching his classes, and publishing in related areas. Also home repair and remodel, snorkling, and cruises to the Carribean.
I am an analyst and 2017 Level III Candidate in the CFA Program that has gained experience in the investment industry through positions as a proprietary trader and a portfolio management administrator. I began contributing to Seeking Alpha as a way to share my thoughts on the biopharmaceutical industry. I discussed ways to minimize risk in biopharmaceutical investing through conservative pipeline valuation and balance sheet analysis to identify companies presenting a compelling valuation to potential investors. I also touched on ways to apply knowledge of the markets to improve personal finance. My pieces included either stock-specific analysis or general biopharmaceutical investing discussion through my Biotech Weekly blog. My research appeared on the websites of CNBC, Seeking Alpha, Reuters, Google Finance, Morningstar, NASDAQ, and MarketWatch.
Note: Articles and comments are my own opinions, are not related to the opinions of my employer, and should not be considered investment advice. Make sure to do your own due diligence before making an investment decision. Thanks!
I was formerly EVP of a major International Investment Bank, and prior to that SVP of a Wall Street retail brokerage firm. I've "retired" to Florida where my involvement with stock and real estate investments takes almost as much of my time as my Wall Street work days.
For over five decades I have been analyzing and investing in stocks and have been through it all, the boom times as well as the crashes. My initial investments were while I was in college pursuing an engineering degree and then an MBA in Finance, and I've been an active investor ever since.
I take an analytical as well as pragmatic approach to investing in stocks with a particular focus on undervalued companies in promising industries. My concentration is with long term growth investments as well as with short term special situations that display promising potential. If the potential with a stock in the latter category materializes, the investment either moves into my long term portfolio or is liquidated with the proceeds plowed back into other worthy investments.
Employing all aspects of technical analysis and market timing, I analyze, evaluate and synthesize individual company profiles, financial data, news releases, market and industry trends, "Stock Watch" lists, analysts’ research, information provided by companies’ Investor Relations staff, etc. I tend to favor firms with rapidly growing sales, a solid balance sheet, high potential product(s) and pertinent insider buying/selling activity.
The lesson that I have learned over the years is NOT to make investments based upon emotion or the hype of the moment, but rather to do due diligence on the relevant facts. If I find that I have made a bad investment decision, I sell it and move on. Emotion should be restricted to loved ones, not investments.